BACKGROUND: The risk for donors of allogeneic hematopoietic stem cells transplants is generally considered negligible. Scattered reports of severe complications and a recent controversy on hematopoietic malignancies after granulocyte colony-stimulating factor administration have challenged this opinion. DESIGN AND METHODS: Three hundred and thirty-eight allogeneic transplant teams from 35 primarily European countries were asked to report numbers of fatalities, severe adverse events and hematologic malignancies occurring among their hematopoietic stem cell donors. RESULTS: Two hundred and sixty-two of the 338 teams (77.5%) responded to a first survey (1993-2002) and 169 of the 262 responder teams (65%) to a second survey (2003-2005). They had performed a total of 51,024 first allogeneic hematopoietic stem cell transplantations, of which 27,770 were bone marrow and 23,254 peripheral blood. They observed five donor fatalities, one after a bone marrow donation and four after peripheral blood donation (incidence 0.98 per 10,000 donations; 95% CI 0.32-2.29), 37 severe adverse events (7.25/10,000; 95% CI 5.11-9.99), of which 12 in bone marrow donors (4.32/10,000; 95% CI 2.24-7.75) and 25 in peripheral blood donors (10.76/10,000; 95% CI 6.97-15.85; p<0.05) and 20 hematologic malignancies (3.92/10,000; 95% CI 2.39-6.05), of which 8 after donating bone marrow and 12 after donating peripheral blood stem cells. The observed incidence rate of hematologic malignancies did not exceed the expected incidence in an age- and sex-adjusted general population. CONCLUSIONS: Hematopoietic stem cell donation is associated with a small but definite risk of fatalities and serious adverse events. True incidences might be higher, due to potential underreporting by study design. A continuous, standardized donor follow-up is needed to define donor risk groups and to monitor intermediate and long-term sequelae.
BACKGROUND: The risk for donors of allogeneic hematopoietic stem cells transplants is generally considered negligible. Scattered reports of severe complications and a recent controversy on hematopoietic malignancies after granulocyte colony-stimulating factor administration have challenged this opinion. DESIGN AND METHODS: Three hundred and thirty-eight allogeneic transplant teams from 35 primarily European countries were asked to report numbers of fatalities, severe adverse events and hematologic malignancies occurring among their hematopoietic stem cell donors. RESULTS: Two hundred and sixty-two of the 338 teams (77.5%) responded to a first survey (1993-2002) and 169 of the 262 responder teams (65%) to a second survey (2003-2005). They had performed a total of 51,024 first allogeneic hematopoietic stem cell transplantations, of which 27,770 were bone marrow and 23,254 peripheral blood. They observed five donor fatalities, one after a bone marrow donation and four after peripheral blood donation (incidence 0.98 per 10,000 donations; 95% CI 0.32-2.29), 37 severe adverse events (7.25/10,000; 95% CI 5.11-9.99), of which 12 in bone marrow donors (4.32/10,000; 95% CI 2.24-7.75) and 25 in peripheral blood donors (10.76/10,000; 95% CI 6.97-15.85; p<0.05) and 20 hematologic malignancies (3.92/10,000; 95% CI 2.39-6.05), of which 8 after donating bone marrow and 12 after donating peripheral blood stem cells. The observed incidence rate of hematologic malignancies did not exceed the expected incidence in an age- and sex-adjusted general population. CONCLUSIONS: Hematopoietic stem cell donation is associated with a small but definite risk of fatalities and serious adverse events. True incidences might be higher, due to potential underreporting by study design. A continuous, standardized donor follow-up is needed to define donor risk groups and to monitor intermediate and long-term sequelae.
Authors: A M Cavallaro; K Lilleby; I Majolino; R Storb; F R Appelbaum; S D Rowley; W I Bensinger Journal: Bone Marrow Transplant Date: 2000-01 Impact factor: 5.483
Authors: G Favre; M Beksaç; A Bacigalupo; T Ruutu; A Nagler; E Gluckman; N Russell; J Apperley; J Szer; K Bradstock; A Buzyn; J Matcham; A Gratwohl; N Schmitz Journal: Bone Marrow Transplant Date: 2003-11 Impact factor: 5.483
Authors: Myrna C Newland; Sheila J Ellis; Carol A Lydiatt; K Reed Peters; John H Tinker; Debra J Romberger; Fred A Ullrich; James R Anderson Journal: Anesthesiology Date: 2002-07 Impact factor: 7.892
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Ann Intern Med Date: 2007-10-16 Impact factor: 25.391
Authors: Petra Sovinz; Wolfgang Schwinger; Herwig Lackner; Andrea Nebl; Sabine Sipurzynski; Christian Urban Journal: Haematologica Date: 2010-04-30 Impact factor: 9.941
Authors: Andrea Bacigalupo; Gérard Socié; Hubert Schrezenmeier; Andre Tichelli; Anna Locasciulli; Monika Fuehrer; Antonio M Risitano; Carlo Dufour; Jakob R Passweg; Rosi Oneto; Mahmoud Aljurf; Catherine Flynn; Valerie Mialou; Rose Marie Hamladji; Judith C W Marsh Journal: Haematologica Date: 2012-02-07 Impact factor: 9.941
Authors: Y Kodera; K Yamamoto; M Harada; Y Morishima; H Dohy; S Asano; Y Ikeda; T Nakahata; M Imamura; K Kawa; S Kato; M Tanimoto; Y Kanda; R Tanosaki; S Shiobara; S W Kim; K Nagafuji; M Hino; K Miyamura; R Suzuki; N Hamajima; M Fukushima; A Tamakoshi; J Halter; N Schmitz; D Niederwieser; A Gratwohl Journal: Bone Marrow Transplant Date: 2013-09-30 Impact factor: 5.483
Authors: A Marmotti; F Castoldi; R Rossi; S Marenco; A Risso; M Ruella; A Tron; A Borrè; D Blonna; C Tarella Journal: Knee Surg Sports Traumatol Arthrosc Date: 2012-08-08 Impact factor: 4.342
Authors: Bronwen E Shaw; Dennis L Confer; William Y Hwang; Derwood H Pamphilon; Michael A Pulsipher Journal: Haematologica Date: 2011-07 Impact factor: 9.941